# Asymmetry Capital Management, L.P.

> Institutional holdings reported to the SEC as of Q4 2021 on Form 13F. CIK 1657134. Source: https://holderbook.com/funds/1657134-asymmetry-capital-management-l-p/

- Reported value: $188.4M
- Positions: 24
- Weight of the ten largest: 64.3%
- Filed: 2022-01-19

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $15.7M | 177,741 | 8.3% | 1 |
| HORIZON THERAPEUTICS PUB L | [HZNP](https://holderbook.com/stocks/HZNP/) | $14.8M | 137,610 | 7.9% | 2 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $13.5M | 26,844 | 7.2% | 1 |
| ABBVIE INC | [ABBV](https://holderbook.com/stocks/ABBV/) | $12.8M | 94,448 | 6.8% | 1 |
| IQVIA HLDGS INC | [IQV](https://holderbook.com/stocks/IQV/) | $12.5M | 44,314 | 6.6% | 1 |
| CENTENE CORP DEL | [CNC](https://holderbook.com/stocks/CNC/) | $12.2M | 148,254 | 6.5% | 1 |
| BELLUS HEALTH INC NEW | [BLU](https://holderbook.com/stocks/BLU/) | $10.3M | 1,280,757 | 5.5% | 2 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $10.3M | 225,032 | 5.4% | 2 |
| JOHNSON & JOHNSON | [JNJ](https://holderbook.com/stocks/JNJ/) | $9.5M | 55,755 | 5.1% | 1 |
| NATERA INC | [NTRA](https://holderbook.com/stocks/NTRA/) | $9.5M | 101,674 | 5.0% | 1 |
| AMICUS THERAPEUTICS INC | [FOLD](https://holderbook.com/stocks/FOLD/) | $8.3M | 716,709 | 4.4% | 3 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $7.3M | 20,881 | 3.9% | 1 |
| KURA ONCOLOGY INC | [KURA](https://holderbook.com/stocks/KURA/) | $7.0M | 502,275 | 3.7% | 2 |
| APELLIS PHARMACEUTICALS INC | [APLS](https://holderbook.com/stocks/APLS/) | $6.6M | 139,445 | 3.5% | 1 |
| MIRATI THERAPEUTICS INC | [MRTX](https://holderbook.com/stocks/MRTX/) | $6.4M | 43,876 | 3.4% | 4 |
| IVERIC BIO INC | [ISEE](https://holderbook.com/stocks/ISEE/) | $6.3M | 375,989 | 3.3% | 2 |
| QUANTERIX CORP | [QTRX](https://holderbook.com/stocks/QTRX/) | $6.1M | 143,204 | 3.2% | 2 |
| ITEOS THERAPEUTICS INC | [ITOS](https://holderbook.com/stocks/ITOS/) | $4.9M | 104,755 | 2.6% | 6 |
| DICE THERAPEUTICS INC | [DICE](https://holderbook.com/stocks/DICE/) | $4.7M | 185,201 | 2.5% | 2 |
| AVADEL PHARMACEUTICALS PLC | [AVDLXXXX](https://holderbook.com/stocks/AVDLXXXX/) | $3.0M | 369,134 | 1.6% | 7 |
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $2.9M | 198,493 | 1.5% | 3 |
| PMV PHARMACEUTICALS INC | [PMVP](https://holderbook.com/stocks/PMVP/) | $2.3M | 97,680 | 1.2% | 6 |
| REGULUS THERAPEUTICS INC | [RGLS](https://holderbook.com/stocks/RGLS/) | $860.0K | 2,731,044 | 0.5% | 4 |
| BCLS ACQUISITION CORP | [BLSA](https://holderbook.com/stocks/BLSA/) | $699.0K | 71,372 | 0.4% | 5 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q4 2021 | -0.7% | +10.7% | -11.4% | 100% |
| Q3 2021 | -9.3% | +0.3% | -9.6% | 100% |
| Q2 2021 | -6.2% | +8.0% | -14.2% | 100% |
| Q1 2021 | -4.2% | +6.0% | -10.2% | 99% |
| Q4 2020 | +13.0% | +11.6% | +1.4% | 99% |
| Q3 2020 | +8.3% | +8.6% | -0.3% | 99% |
| Q2 2020 | +35.0% | +19.6% | +15.4% | 100% |
| Q1 2020 | -9.1% | -19.9% | +10.8% | 98% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2021 | $188.4M | 24 |
| Q3 2021 | $166.3M | 29 |
| Q2 2021 | $145.5M | 30 |
| Q1 2021 | $193.3M | 29 |
| Q4 2020 | $219.3M | 33 |
| Q3 2020 | $155.6M | 34 |
| Q2 2020 | $130.5M | 32 |
| Q1 2020 | $91.4M | 29 |
| Q4 2019 | $55.8M | 33 |
| Q3 2019 | $46.7M | 22 |
| Q2 2019 | $184.7M | 30 |
| Q1 2019 | $59.8M | 25 |